| Symbol | OTLC |
|---|---|
| Name | ONCOTELIC THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 91301 United States CA 29397 Agoura Road Suite 107 |
| Telephone | (650)635-7000 |
| Fax | — |
| — | |
| Website | http://www.oncotelic.com |
| Incorporation | US |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | Rose, Snyder & Jacobs; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0000908259 |
| Description | Oncotelic Therapeutics, Inc. (OTLC) are developing three lines of therapeutics. 1) Oncology/Virology - we are developing OT-101 (TGF-beta antisense/ Artemisinin).against certain oncology indications and viral infections. The program is being funded by our partner GMP through a JV that we are intend to take IPO. In addition, we are developing our VDA agents (Oxi4503/CA4P) various tumors, including three rare pediatric tumors (DIPG, Melanoma, and AML). 2) AL-101 (intranasal-apomorphine) for the treatment of Parkinson Disease, Erectile Dysfunction not responding to PDE5 inhibitor, and Female Sexual Dysfunction. 3) Animal health product including oncology (CA4P and Artemishas). Additional info from OTC: |
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
Read moreOncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003
Read moreOncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
Read moreSapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
Read moreOncotelic Therapeutics Inc. (OTCQB: OTLC) Advancing Proprietary Solutions Focused on Nanotechnology-Enabled Drug Delivery, AI-Enhanced Biomedical Infrastructure
Read moreOncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
Read moreSapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
Read moreOncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
Read moreOncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease
Read more